...
首页> 外文期刊>International archives of allergy and immunology >Allergen chip diagnosis for soy-allergic patients: Gly m 4 as a marker for severe food-allergic reactions to soy
【24h】

Allergen chip diagnosis for soy-allergic patients: Gly m 4 as a marker for severe food-allergic reactions to soy

机译:大豆过敏患者的过敏原芯片诊断:Gly m 4作为对大豆的严重食物过敏反应的标志物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Gly m 5 and Gly m 6 are known to induce severe reactions in soy-allergic patients. For birch pollen (BP)-allergic patients, the Bet v 1 homologous allergen Gly m 4 is also a potential trigger of generalized severe reactions upon soy consumption. Therefore, reliable component-resolved diagnosis of soy allergy is needed. Methods: IgE reactivity from sera of 20 patients from a BP environment with reported soy allergy was assessed. Skin prick tests (SPT) with BP and soy drink were performed. Specific IgE for BP, soy, Bet v 1 and Gly m 4 was analyzed by ImmunoCAP. In addition, ISAC microarray profiling was performed. Results: Nineteen of 20 patients were BP allergic (positive SPT and/or CAP results for BP extract and Bet v 1). Eighteen soy-allergic patients were tested positive with soy drink in SPT. Soy CAP results were negative in the majority of tests (15/20), whereas 19/20 sera had specific IgE to Gly m 4. In the microarray approach, 14/20 sera displayed Gly m 4-specific IgE, the additional 6 sera had IgE levels below 0.3 ISAC standardized units. The BP-negative serum had Gly m 5-and Gly m 6-specific IgE which correlated with positive soy ImmunoCAP. Conclusions: Soy sensitization detected by SPT and Gly m 4 ImmunoCAP were in good qualitative agreement with ISAC results. Soy ImmunoCAP was only specific for Gly m 5 and Gly m 6 sensitization. Gly m 4 ImmunoCAP has a higher sensitivity than ImmunoCAP ISAC. In this patient cohort, Gly m 4 sensitization was linked to the development of severe and generalized allergic reactions upon soy consumption.
机译:背景:已知Gly m 5和Gly m 6在大豆过敏患者中引起严重反应。对于桦树花粉(BP)过敏的患者,Bet v 1同源变应原Gly m 4也是大豆摄入后普遍严重反应的潜在诱因。因此,需要可靠的成分分辨的大豆过敏诊断。方法:评估了来自20例患有BP环境且有大豆过敏报道的患者的IgE反应性。用BP和大豆饮料进行皮肤点刺试验(SPT)。 ImmunoCAP分析了BP,大豆,Bet v 1和Gly m 4的特异性IgE。另外,进行了ISAC微阵列分析。结果:20位患者中有19位是BP过敏(BP提取物和Bet v 1的SPT和/或CAP结果均为阳性)。在SPT中,对18名大豆过敏患者的大豆饮料测试为阳性。在大多数测试中(15/20),大豆CAP结果均为阴性,而19/20血清对Gly m 4具有特异性IgE。在微阵列方法中,14/20血清显示Gly m 4特异性IgE,另外6个血清IgE水平低于0.3 ISAC标准化单位。 BP阴性血清具有Gly m 5和Gly m 6特异性IgE,与阳性大豆ImmunoCAP相关。结论:SPT和Gly m 4 ImmunoCAP检测到的大豆致敏性与ISAC结果具有良好的定性一致性。大豆ImmunoCAP仅对Gly m 5和Gly m 6致敏。 Gly m 4 ImmunoCAP的灵敏度高于ImmunoCAP ISAC。在该患者队列中,Gly m 4致敏与食用大豆后发生严重的全身性过敏反应有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号